The Arizona Center for Innovation (AzCI) is pleased to announce that the Flinn Foundation has selected MSDx, Inc. to receive grant funding and program services through the Foundation’s 2013 Bioscience Entrepreneurship Program. MSDx is a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders such as Multiple Sclerosis (MS). The Foundation funding will be used to support further development of the MSDx blood testing technology.
Tag Archives: MSDx
MSDx Announces Issuance of First Patent for Monitoring Disease Activity in a Multiple Sclerosis Patient
TUCSON, AZ, September 17, 2013 – MSDx, Inc., a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders, announced today that the United States Patent and Trademark Office issued a patent that broadly protects the company’s exclusive rights for monitoring or detecting Multiple Sclerosis (MS) in a patient, utilizing its proprietary technology.Continue reading
Seven Arizona Companies Selected to Present to Investors in Denver
Applied Microarrays Inc., Convoy Therapeutics, ENDURX Pharmaceuticals, Inc., MSDx, Nasseo, Inc., Solvonics Medical will be representing Arizona’s life science innovation community at the Rocky Mountain Life Science Investor and Partnering Conference (RMLSIPC) in Denver this September.Continue reading
MSDx Welcomes David McCaleb to its Board of Directors
MSDx, Inc., announced today that David McCaleb has joined its Board of Directors. With over thirty years of experience in leading pharmaceutical companies and biotech start-ups, his successful track record in commercialization and fundraising will augment the MSDx team. Continue reading
MSDx, Inc. Awarded a Rapid Response Innovation Grant
MSDx, Inc. Awarded a Rapid Response Innovation Grant from The Michael J. Fox Foundation For the Development of Biomarkers in Parkinson’s DiseaseContinue reading
MSDx seeks USD 5m first VC round for blood-based multiple sclerosis monitoring assay, CEO says
BioPharm Insight Profiles MSDxContinue reading